pentobarbital will decrease the extent or effect of alfentanil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unknown.
pentobarbital will decrease the level or impact of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will lower the extent or influence of tramadol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. Reduced AUC of tramadol and the Lively metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
pentobarbital will reduce the level or outcome of oxybutynin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unidentified.
pentobarbital will lessen the level or influence of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will reduce the extent or result of carvedilol by affecting hepatic enzyme CYP2C9/10 metabolism. Use Warning/Keep an eye on.
fentanyl transdermal and pentobarbital both increase sedation. Steer clear of or Use Alternate Drug. Limit use to patients for whom choice therapy selections are insufficient
pentobarbital will reduce the level or outcome of buprenorphine subdermal implant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Intently. Keep an eye on individuals by now on buprenorphine subdermal implant who involve newly-initiated cure with CYP3A4 inducer for symptoms and symptoms of withdrawal.
pentobarbital will lessen the extent or result of pimozide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.
pentobarbital will lessen the extent or impact of fludrocortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will lessen the level or impact of duvelisib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Coadministration with a powerful CYP3A inducer decreases duvelisib region under the curve (AUC), which may minimize duvelisib efficacy.
pentobarbital will reduce the level or result of fedratinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Keep away from or Use Alternate Drug. Effect of here coadministering a strong CYP3A4 inducer with fedratinib hasn't been researched.
pentobarbital will reduce the extent or influence of mestranol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
Monitor Carefully (one)pentobarbital will reduce the level or outcome of fentanyl transmucosal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of fentanyl with CYP3A4 inducers may lead to a lessen in fentanyl plasma concentrations, not enough efficacy or, possibly, development of the withdrawal syndrome inside a client who may have produced physical dependence to fentanyl. Soon after stopping a CYP3A4 inducer, since the effects on the inducer decline, the fentanyl plasma focus will improve which could enhance or extend both the therapeutic and adverse effects.